Article info
PDFClinical and epidemiological research
Extended report
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
- Correspondence to Dr Philip J Mease, Swedish Medical Center and University of Washington, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122, USA; pmease{at}philipmease.com
Citation
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
Publication history
- Received October 25, 2016
- Revised March 16, 2017
- Accepted March 29, 2017
- First published May 4, 2017.
Online issue publication
October 31, 2019
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/